DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) ā Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of terbutaline on force and intracellular calcium in slow-twitch skeletal muscle fibres of the rat. | 1999 Apr |
|
[Early stage of cardiomyopathy: mechanisms of damage and compensation]. | 1999 Jul |
|
C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein. | 2000 Apr |
|
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 Dec |
|
Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. | 2000 Feb 1 |
|
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | 2000 Jan 7 |
|
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. | 2000 Nov |
|
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells. | 2000 Nov |
|
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
ATP induces dephosphorylation of myosin light chain in endothelial cells. | 2000 Sep |
|
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy. | 2001 Jun 8 |
|
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
Effect of calcium phosphate and vitamin Dā supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014 Jan 17 |
|
Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate. | 2018 Mar |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
||
|
WHO-VATC |
QA12AA01
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
||
|
EPA PESTICIDE CODE |
76401
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
||
|
WHO-ATC |
A12AA01
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
||
|
LOINC |
32137-2
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB127040
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
ALTERNATIVE | |||
|
C45678
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
1919
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
97Z1WI3NDX
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
9679
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
10103-46-5
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
97Z1WI3NDX
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
SUB127041
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
ALTERNATIVE | |||
|
C120560
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
100000088337
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
C020243
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
SUB20364
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
233-283-6
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
4441
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
SUB127042
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
ALTERNATIVE | |||
|
DB11348
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY | |||
|
DTXSID40893099
Created by
admin on Fri Dec 15 16:04:19 GMT 2023 , Edited by admin on Fri Dec 15 16:04:19 GMT 2023
|
PRIMARY |
Any of these components may be present:
ACTIVE MOIETY
SUBSTANCE RECORD